| | | | |
CUSIP No. 35803L108 | | Schedule 13G | | Page 2 of 4 |
ITEM 1. (a) | Name of Issuer: |
Frequency Therapeutics, Inc. (the “Issuer”).
| (b) | Address of Issuer’s Principal Executive Offices: |
75 Hayden Avenue, Suite 300, Lexington, MA 02421.
ITEM 2. (a) | Name of Person Filing: |
This statement is filed on behalf of David L. Lucchino (the “Reporting Person”).
| (b) | Address or Principal Business Office: |
The business address of the Reporting Person is c/o Frequency Therapeutics, Inc., 75 Hayden Avenue, Suite 300, Lexington, MA 02421.
The Reporting Person is a citizen of the United States.
| (d) | Title of Class of Securities: |
Common stock, par value $0.001 per share (“Common Stock”).
35803L108
Not applicable.
ITEM 4. Ownership.
The ownership information below represents beneficial ownership of shares of Common Stock as of the date hereof, based upon 36,520,750 shares of Common Stock outstanding as of August 1, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2023.
| (a) | Amount beneficially owned: |
The Reporting Person may be deemed to beneficially own 2,368,527 shares of Common Stock, which includes (i) 633,744 shares of Common Stock and (ii) 1,734,783 shares of Common Stock underlying stock options that are exercisable or will become exercisable within 60 days of the date hereof.